Trial
NCT03287245
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Hoffmann-La Roche
Collaborators
—
Condition
Polycythemia Vera
Intervention
Idasanutlin
Why stopped
The Sponsor decided to discontinue the development of idasanutlin in the polycythemia vera indication.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-12-08